Naviter Wealth LLC Sells 421 Shares of Thermo Fisher Scientific Inc. $TMO

Naviter Wealth LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,854 shares of the medical research company’s stock after selling 421 shares during the period. Naviter Wealth LLC’s holdings in Thermo Fisher Scientific were worth $1,564,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. CBIZ Investment Advisory Services LLC raised its stake in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares in the last quarter. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific in the first quarter worth approximately $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the first quarter worth approximately $31,000. IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the first quarter worth approximately $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in Thermo Fisher Scientific in the first quarter worth approximately $37,000. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research note on Thursday, July 24th. Barclays upped their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. HSBC reaffirmed a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. William Blair initiated coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $589.10.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $525.08 on Wednesday. The firm has a market capitalization of $198.28 billion, a PE ratio of 30.37, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company’s fifty day moving average price is $491.00 and its 200-day moving average price is $448.20.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the company earned $5.37 earnings per share. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.